Insider sale of $63,352 in stock signals potential shift in executive confidence amid recent pipeline developments.
Spero Therapeutics CEO sold $63,352 worth of company shares, according to a recent filing. The transaction reduces the executive’s direct holdings in the clinical-stage biopharmaceutical firm.
The sale follows a mixed quarterly update, where Spero reported progress in its lead antibiotic candidate but missed revenue estimates. Comparable insider activity in the sector has often preceded strategic shifts or financing events.
SPRO shares showed muted reaction in after-hours trading, holding near the prior close of $2.15.